In accordance with a licensing and distribution agreement with Par Pharmaceutical Companies, Par began immediate shipments of the 150mg strength tablets after the approval of another generic product, Bradley said.
“While this strength of Adoxa represented approximately 18.5% of Bradley’s 2006 net sales, we proactively planned for this launch to commence once a generic version became available,” said Daniel Glassman, president and CEO of Bradley Pharmaceuticals.
“Since 2005, Par has been our exclusive partner with authorized generic Adoxa formulations and maintains about a 55% market share of previous formulations of Adoxa generics, including the 50 mg and 100 mg strengths of Adoxa.”